Lords Mark Industries Ltd

Collaboration overview

• Purpose: strategic partnership to establish and operate pathology labs and commercialise IVD and MedTech across the Caribbean.
• Funding: ARKALL to invest 100% of expansion costs.
• Lords Mark will supply IVD products, provide training, and regulatory support.
• Market rollout: Phase 1 in Trinidad and Tobago; phased expansion over three years.

Financial outlook and governance

• Projected export revenue around US$100 million between FY27-FY31.
• Total pathology and diagnostics opportunity across the Caribbean estimated at US$1.24 billion.
• Outlook subject to regulatory approvals, market penetration, and successful execution.
• Related parties: promoter group has no interest in ARKALL.

Business overview

• Diversified group with LED/renewables and IVD/Medtech businesses.
• Dialysis machines manufactured under BEL; IIT Bombay and BARC tech in development.
• 28-year-old firm listed via reverse merger in July 2026.

Operational highlights

• Q1 FY27 topline around ₹280 crore; PAT around ₹32 crore.
• FY27 revenue guidance ₹1,550 crore; >20% growth.
• LED/renewables order book ₹3,000 crore; dialysis >500 machines.
• Medtech products from IIT Bombay and BARC to launch FY27/28.
• Plan to set up 50 dialysis centers this fiscal year.
• Aviatic Private Limited formed for new business; disclosure to follow.

Financial performance

• Medtech EBITDA margin ~20%; Renewables EBITDA ~11%.
• Dialysis machine ASP ~₹7.5 lakh; manufacturing cost ~₹4.5 lakh.

Capital structure & liquidity

• Promoter stake ~80%; dilution to 75% via OFS/ rights under discussion.
• Listed via reverse merger on 10 July 2026.
• Aviatic formation indicates new business; disclosures to follow.
• Regulatory approvals required for IIT Bombay/ BARC cancer testing tech (ICMR/CDSCO).

Strategic priorities & outlook

• Guidance for >20% YoY revenue growth; Medtech to contribute ≥30%.
• Launch sickle cell and Onco TB Truth by FY27/28; additional Onco products.
• Plan to set up 50 dialysis centers; hospitals and pathology labs expansion.
• Pursue government opportunities in sickle cell testing and cancer diagnostics.

Risks & mitigations

• Sickle cell mission pricing not yet fixed; tender-based approvals pending.
• ICMR/CDSCO approvals required for new Medtech technologies.

Governance & leadership

• Post-merger, auditors and company secretary exits; new appointments expected.
• Board evaluating promoter dilution path (OFS vs rights) under discussion.

Meeting details

• Investor Call held on 19 August 2026 to discuss progress, operations, and Q1 FY27 updates.

Recording availability

• Audio and video recording uploaded to the company website.

Rating Action

• Long-term rating upgraded to IVR A-/Stable; short-term rating upgraded to IVR A2+.

Instruments Rated

• Total bank facilities rated: Rs 260.37 crore (enhanced from Rs 191.03 crore).

Rating Agency

• Agency: Infomerics Valuation and Rating Ltd.

Rationale

• Based on FY25 audited and FY26 provisional performance; detailed rationale not disclosed.

Outlook

• Long-term outlook: Stable; short-term outlook not separately stated.

Material Changes

• Facilities enhanced; total rated amount increased from Rs 191.03 crore to Rs 260.37 crore.

Timing

• Date of rating communication: August 17, 2026.

Financial Highlights

• No specific revenue/profit metrics cited in the rationale.

Investor Meet details

• Invitation to participate in online Investor Meet on 19 August 2026 at 04:00 p.m. IST.
• Mode: Online; Meeting link: https://meet.zoho.in/mpys-xzh-rie
• Purpose: discuss company's progress on business and operations.
• Date of invitation letter: 17 August 2026.
• Issuer: Lords Mark Industries Limited.

HP Adhesives Q1 FY27 results

• Standalone Q1 FY27 total income 28,036.22 Lakhs; net profit after tax 3,216.44 Lakhs; EPS 0.75.
• Consolidated Q1 FY27 total income 30,768.21 Lakhs; net profit after tax 3,318.23 Lakhs; EPS 0.78.

LORD'S MARK INDUSTRIES LIMITED – Q1 FY27 results

• Standalone Q1 FY27 total income 28,036.22 Lakhs; net profit after tax 3,216.44 Lakhs; EPS 0.75.
• Consolidated Q1 FY27 total income 30,768.21 Lakhs; net profit after tax 3,318.23 Lakhs; EPS 0.78.
• Board approved results on Aug 13, 2026; results hosted on company website.

RISHABH DIGHA STEEL AND ALLIED PRODUCTS LIMITED – Q1 2026 results

• Board approved unaudited standalone and consolidated results for quarter ended 30 Jun 2026; data posted on stock exchanges.

ELPRO INTERNATIONAL LIMITED – Q1 2026-27 results

• Board approved audited Q1 FY27 results; posted on the company website.

AGM calendar details

• Board approved the AGM calendar and notice on August 13, 2026.
• 46th AGM to be held on September 30, 2026 at 11:30 AM IST via VC/OAVM.
• Cut-off date to vote on AGM resolutions: September 23, 2026.
• Remote e-voting opens September 27, 2026 and closes September 29, 2026 (9:00–17:00 IST).
• E-voting provider NSDL and Scrutinizer Geeta Serwani, PCS.

Key updates

• FY2027 revenue guidance at least ₹1,550 crore; PAT at least ₹178 crore; margin 11.4%.
• Growth: revenue up >20% and PAT up >50% vs FY2026; base growth from diagnostics, renewable energy.
• Proposed demerger of Renewable Energy & LED into Lords Shakti Power Limited; Company to hold 60% by 2027.
• Exclusive India CAR-T agreement; five centres; first two in Mumbai and Bengaluru; commercialization by March 2027.
• UK subsidiary Lords Mark Industries UK Limited to operate pathology lab; NHS approval submitted; target January 2027.
• Swiss subsidiary Lords Mark Industries Swiss Limited under process; same business plan as UK entity.
• Oncology hospitals: Lords Mark Medicine Limited; two pilots at Vapi and Solapur; ~₹200 crore debt planned December 2026.
• Dialysis centre network: 50 centres by March 2027; rented premises; 3–5 RENALOS machines per centre.
• OneDNA platform: patient trials completed; ICMR approval received; CDSCO application ongoing.
• Biomescan SaMD: manufacturing licence received; first Indian company to obtain licence; wellness and health-risk tool.

Standalone performance

• Income from operations: 28,036.22 Rs Lacs.
• Total income: 28,522.32 Rs Lacs.
• PBT: 4,392.24 Rs Lacs; tax: 1,175.80.
• Net profit: 3,216.44 Rs Lacs; EPS 0.75.

Consolidated performance

• Income from operations: 30,768.21 Rs Lacs.
• Total income: 31,266.50 Rs Lacs.
• PBT: 4,547.22 Rs Lacs; tax: 1,229.00.
• Net profit: 3,318.23 Rs Lacs; EPS 0.78.

Financial results

• Standalone and Consolidated unaudited results for quarter ended 30 June 2026 approved with Limited Review Report

Annual report & governance

• Board-approved Board's Report, MD&A, Corporate Governance Report for year ended 31 March 2026

AGM planning

• 46th AGM scheduled Sept 30, 2026 at 11:30 AM via VC/OAVM
• Record date fixed at Sept 23, 2026
• Remote e-voting from Sept 27 to Sept 29, 2026
• NSDL appointed as remote e-voting provider
• Scrutinizer appointed: Geeta Serwani

Calendar & notices

• Calendar of Events for the 46th AGM approved

Key personnel changes

• Resignation tendered by Ms. Bhavini Rajkumar Chandnani as Company Secretary & Compliance Officer
• Relief from duties effective close of business Aug 20, 2026

Auditors and secretarial appointments

• Statutory Auditor: M/s Sanjeev S. Gupta & Associates recommended for 5-year term from 46th AGM
• Secretarial Auditor: Geeta Serwani & Associates for 5 financial years from FY2026-27
• Internal Auditor: M/s E Srinivas and Co for FY2026-27 to FY2028-29
• Cost Auditor: M/s Raj Kaushik & Associates for FY2026-27; remuneration to be ratified at AGM

Governance & corporate actions

• Authorized Sachidanand Upadhyay to sign documents for subsidiaries, acquisitions, mergers, and amalgamations
• Authorized restructuring and strengthening of Kratos Energy Infrastructure Limited management

Trading window

• Trading window remains closed; reopens 48 hours after results release